

Concise Enantioselective Synthesis of ent-Malbrancheamide B

Frederic Frebault,[†] Nigel S. Simpkins,^{†,*} and Ashley Fenwick[‡]*School of Chemistry, The University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K., and Pfizer Central Research (Animal Health), Ramsgate Road, Sandwich CT13 9NJ, U.K.*

Received January 28, 2009; E-mail: n.simpkins@bham.ac.uk

There is a growing family of fungi-derived alkaloids whose members feature a bicyclo[2.2.2]diazaoctane core as part of a more complex polycyclic structure.¹ Important examples include brevianamide B (**1**), paraherquamide A (**2**), stephacidin A (**3**), and the most recently added members of the group, the malbrancheamides **4** and **5** (Figure 1).²

These compounds combine synthetically challenging structures, intriguing biosynthetic origins, and, in many cases, potent biological activities. The malbrancheamides, recently isolated from the fungus *Malbranchea aurantiaca*, are unique in having a chlorinated indole nucleus, and compound **4** was shown to be a new calmodulin (CaM) inhibitor.^{2a,3}





Figure 1. Structures of natural products containing bicyclo[2.2.2]-diazaoctane.

The synthesis and biosynthesis of these compounds have been probed for many years, most notably by the Williams group, which has established a biomimetic IMDA strategy as a concise access to several members of this family of natural products, including malbrancheamides **4** and **5**.⁴ However, because of the prochiral nature of the key intermediate in this sequence, the products are necessarily racemic.⁵ Herein, we describe a new and general enantioselective approach to this type of compound, which we illustrate with a concise synthesis of ent-malbrancheamide B (**5**).


Our chosen penultimate synthesis intermediate was 5-oxamalbrancheamide B (**6**), which had been previously synthesized by Williams^{4a} and shown to be reduced to **5** by the action of DIBAL-H (Scheme 1). This compound would be formed by double cyclization of hydroxydiketopiperazine (hydroxy-DKP) compound **8** via the unusual α -amido *N*-acyliminium species **7**.

Model studies indicated that such a cyclization should predominantly give the stereochemistry at C-12a required for the malbrancheamides.⁶ The key intermediate **8** would be

Scheme 1. Retrosynthetic Analysis of Malbrancheamide B

generated by union of a suitably protected prenylated proline amide **9** (P = protecting group) and the indole-3-pyruvic acid derivative **10**. As several other groups have done, we initially chose to explore our synthesis in the unnatural series, because of the relative cheapness of L-proline.

Potentially suitable proline amide derivatives conforming to the generic structure **9** were readily available using the Seebach “self-reproduction of chirality” approach.⁷ After exploring a number of alternatives, we settled on the use of the *O*-benzylhydroxamic acid derivative **13**, which is easily prepared from the “Seebach acetal” **11** via prenylated derivative **12** (Scheme 2).⁸

Scheme 2. Synthesis of Hydroxamic Acid Derivative **13a**

^a Reagents and conditions: (a) LDA, THF, -78°C , prenyl bromide, 76%; (b) BnONH₂, *n*-BuLi, THF, -78°C , 75%.


Attempts at direct coupling of such proline amides with pyruvic acid **10** were presumably thwarted by the intervention of the enol form of the keto acid, which completely undermined the usual amide-forming protocols.⁹ To avoid this problem, we employed the tactic of coupling an enol ether derivative corresponding to **10**.

Readily prepared aldehyde **14** was condensed with ester **15** to give aldol adduct **16** as a 4:1 mixture of diastereomers (Scheme 3). This compound underwent ready elimination via mesylation and base treatment to give an unsaturated ester, which was then hydrolyzed to give acid **17** (3:1 *Z/E*).

With the troublesome α -keto acid function of the indole pyruvic acid system suitably protected, the required coupling with proline

[†] University of Birmingham.

[‡] Pfizer Central Research.

Scheme 3. Amide Coupling and DKP Formation^a


^a Reagents and conditions: (a) LHMDS, THF, $-78\text{ }^{\circ}\text{C}$, 97%; (b) MsCl, CH_2Cl_2 , Et_3N , then DBU, 91%; (c) LiOH, THF(aq), 58% (+14% N-H derivative + 12% rec SM); (d) HATU, *i*-PrNEt₂, MeCN, 74%; (e) *i*-PrOH, CBr₄, $50\text{ }^{\circ}\text{C}$, 52%.

amide **13** proceeded smoothly to give the anticipated OSEM ether product **18** as a mixture of *Z* and *E* isomers. Unexpectedly, SEM ether **18** resisted all attempts at deprotection using TBAF, TBAT, or HF-py.¹⁰ After screening alternative acidic conditions, we eventually established that conversion of **18** into the key DKP **19** was possible, albeit in moderate yield, by use of CBr₄ in warm *i*-PrOH.¹¹

With our key precursor DKP **19** in hand, we were delighted to observe that treatment of this compound with TMSOTf in CH_2Cl_2 resulted in smooth cyclization accompanied by loss of the indole NBoc group (Scheme 4). The desired polycyclic DKP **20** was obtained in 64% yield as a separable 4:1 mixture favoring the desired C12a epimer.¹² The major product arises from a preferred conformation of the intermediate **7** in which the prenyl group is oriented away from the OBn group on nitrogen.

Conversion of **20** into ent-malbrancheamide B (**5**) was then accomplished by reductive cleavage of the N–OBn linkage using SmI₂ in the presence of excess LiCl¹³ followed by reduction according to the published Williams protocol. Our synthetic ent-malbrancheamide B (**5**) displayed spectroscopic properties fully in accord with those published previously.¹⁴

The efficiency of our total synthesis of ent-malbrancheamide B is, at present, compromised by several steps having modest yields, especially the SEM removal leading to **19**, but the route is very concise, requiring only 10 steps from commercial 6-chloroindole. Further streamlining of the route and its application to other natural products in this family are underway.

Scheme 4. Completion of the Malbrancheamide B Synthesis^a

^a Reagents and conditions: (a) TMSOTf, CH_2Cl_2 , $0\text{ }^{\circ}\text{C}$ to RT, 64%, 4:1 dr; (b) SmI₂, LiCl, THF, RT, 70%; (c) DIBAL-H, toluene, RT, 63% (74%^{4a}).

Acknowledgment. We acknowledge Pfizer, Sandwich, U.K., and the Universities of Nottingham and Birmingham for support of F.F. through a studentship. We also thank Dr. Richard Webster (Pfizer) for his support of this work.

Supporting Information Available: Complete experimental details and characterization data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) (a) For a review, see: Williams, R. M.; Cox, R. J. *Acc. Chem. Res.* **2003**, *36*, 127. (b) For leading references, see: Ding, Y.; Gruschow, S.; Greshock, T. J.; Finefield, J. M.; Sherman, D. H.; Williams, R. M. *J. Nat. Prod.* **2008**, *71*, 1574.
- (2) (a) Martínez-Luis, S.; Rodríguez, R.; Acevedo, L.; González, M. C.; Lira-Rocha, A.; Mata, R. *Tetrahedron* **2006**, *62*, 1817. (b) Figueroa, M.; Del Carmen González, M.; Mata, R. *Nat. Prod. Res.* **2008**, *22*, 709.
- (3) Miller, K. A.; Figueroa, M.; Valente, M. W. N.; Greshock, T. J.; Mata, R.; Williams, R. M. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 6479.
- (4) (a) Miller, K. A.; Welch, T. R.; Greshock, T. J.; Ding, Y.; Sherman, D. H.; Williams, R. M. *J. Org. Chem.* **2008**, *73*, 3116. Also see: (b) Ding, Y.; Greshock, T. J.; Miller, K. A.; Sherman, D. H.; Williams, R. M. *Org. Lett.* **2008**, *10*, 4863. (c) Valente, M. W. N.; Williams, R. M. *Heterocycles* **2006**, *70*, 249.
- (5) This assumes that no bystander asymmetric centers are present; see ref 1 for examples.
- (6) Pichowicz, M.; Simpkins, N. S.; Blake, A. J.; Wilson, C. *Tetrahedron* **2008**, *64*, 3713.
- (7) Seebach, D.; Boes, M.; Naef, R.; Schweizer, W. B. *J. Am. Chem. Soc.* **1983**, *105*, 5390.
- (8) A number of alternatives, including *N*-PMB, *N*-DMB, and *N*-allyl were prepared but either proved incompatible with subsequent steps or could not be removed efficiently later on.
- (9) Non-benzylic types of pyruvic acids can be coupled effectively. See: Siwicki, A.; Wojtasiewicz, K.; Rosiek, B.; Leniewski, A.; Maurin, J. K.; Czarnocki, Z. *Tetrahedron: Asymmetry* **2005**, *16*, 975.
- (10) More usual ethers, including OMe and OPMB types, were tried first, but this system appears to be unexpectedly stable toward acidic reagents, presumably because of the push–pull nature of the extended conjugated indole carboxamide. Forcing conditions resulted in destruction of the starting materials with no constructive cyclization.
- (11) Chen, M.-Y.; Lee, A. S.-Y. *J. Org. Chem.* **2002**, *67*, 1384.
- (12) This type of cyclization is completely diastereoselective if the ring nitrogen bears a PMB group, but this is not easily removed later (see ref 1).
- (13) Fuchs, J. R.; Mitchell, M. L.; Shabangi, M.; Flowers, R. A., III. *Tetrahedron Lett.* **1997**, *38*, 8157.
- (14) We thank Professor R. M. Williams (Colorado State University) and Professor R. Mata (Instituto de Biología, Universidad Nacional Autónoma de México) for their assistance in clarifying the identity of our synthetic sample.

JA900688Y